We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

162 hedge funds and large institutions have $873M invested in Achillion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

196% more call options, than puts

Call options by funds: $13M | Put options by funds: $4.38M

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

30% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 44

10% more funds holding

Funds holding: 147 → 162 (+15)

2% more capital invested

Capital invested by funds: $852M → $873M (+$20.3M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
162
Holders Change
+15
Holders Change %
+10.2%
% of All Funds
4.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
25
Increased
57
Reduced
44
Closed
9
Calls
$13M
Puts
$4.38M
Net Calls
+$8.59M
Net Calls Change
+$2.19M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$12.9M
2
O
OrbiMed
New York
+$12.1M
3
PA
Perceptive Advisors
New York
+$7.9M
4
TCP
Tourbillon Capital Partners
New York
+$7.88M
5
NI
Numeric Investors
Massachusetts
+$7.6M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$37.4M
2
Millennium Management
Millennium Management
New York
-$26.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$15.9M
5
JP Morgan Chase
JP Morgan Chase
New York
-$5.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
51
Bellevue Group
Switzerland
$1.94M -$1.53M -180,000 -43%
SCA
52
Secor Capital Advisors
New York
$1.8M +$1.15M +135,663 +156%
AllianceBernstein
53
AllianceBernstein
Tennessee
$1.62M – – –
DCM
54
DAFNA Capital Management
California
$1.51M -$425K -50,000 -21%
Swiss National Bank
55
Swiss National Bank
Switzerland
$1.48M -$57K -6,700 -4%
VM
56
VHCP Management
New York
$1.46M +$1.53M +180,000 New
AA
57
ALPS Advisors
Colorado
$1.41M -$151K -17,707 -9%
California Public Employees Retirement System
58
California Public Employees Retirement System
California
$1.38M -$100K -11,800 -6%
Creative Planning
59
Creative Planning
Kansas
$1.27M +$206K +24,276 +18%
CS
60
Credit Suisse
Switzerland
$1.27M -$403K -47,404 -23%
HCM
61
Highbridge Capital Management
New York
$1.25M +$1.07M +126,044 +437%
UBS Group
62
UBS Group
Switzerland
$1.24M -$346K -40,701 -21%
Wells Fargo
63
Wells Fargo
California
$1.2M -$130K -15,334 -9%
EA
64
Emerald Acquisition
Washington
$1.1M -$363K -42,685 -24%
CCI
65
Columbus Circle Investors
$1.09M +$206K +24,214 +22%
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$1.09M +$56.1K +6,600 +5%
JP Morgan Chase
67
JP Morgan Chase
New York
$1.05M -$5.14M -604,860 -82%
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$1.03M +$22.1K +2,604 +2%
Two Sigma Investments
69
Two Sigma Investments
New York
$1.02M +$960K +112,934 +907%
Dimensional Fund Advisors
70
Dimensional Fund Advisors
Texas
$1.01M – – –
RJA
71
Raymond James & Associates
Florida
$907K +$66.2K +7,784 +7%
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
$832K +$287K +33,751 +49%
Tudor Investment Corp
73
Tudor Investment Corp
Connecticut
$831K +$704K +82,766 +417%
ProShare Advisors
74
ProShare Advisors
Maryland
$792K -$155K -18,273 -16%
BG
75
BlackRock Group
United Kingdom
$750K +$380K +44,678 +93%
1 2
3
4 5

ACHN Hedge Fund Activity: Q3 2016 in Review

162 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2016, worth a combined $873M — up 2.4% from $852M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ACHN positions and 9 closed out — a net gain of 16 holders — while 57 added to existing stakes and 44 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $12.9M. The largest seller was Fidelity Investments, cutting an estimated $37.4M.

  • 162 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2016, up from 147 in Q2 2016.
  • Funds reported $873M of Achillion Pharmaceuticals stock for Q3 2016, up 2.4% quarter-over-quarter.
  • 25 funds opened new Achillion Pharmaceuticals positions in Q3 2016 and 9 closed out, a net change of +16 holders.
  • The largest Achillion Pharmaceuticals buyer in Q3 2016 was Goldman Sachs, an estimated $12.9M added.
  • The largest Achillion Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $37.4M sold.

Based on aggregated 13F filings for Q3 2016.